Credit Suisse Group reiterated their neutral rating on shares of Smith & Nephew plc (LON:SN) in a report published on Friday. Credit Suisse Group currently has a GBX 1,280 ($16.68) price target on the stock.
A number of other research analysts also recently commented on the stock. Shore Capital reaffirmed a hold rating and set a GBX 1,144 ($14.90) price objective on shares of Smith & Nephew plc in a research report on Friday, May 5th. J P Morgan Chase & Co lowered their price objective on shares of Smith & Nephew plc from GBX 1,345 ($17.52) to GBX 1,280 ($16.68) and set a neutral rating on the stock in a research report on Monday, May 15th. HSBC Holdings plc reaffirmed a hold rating and set a GBX 1,320 ($17.20) price objective on shares of Smith & Nephew plc in a research report on Wednesday, April 26th. Morgan Stanley reaffirmed an overweight rating on shares of Smith & Nephew plc in a research report on Monday, May 15th. Finally, Numis Securities Ltd reaffirmed an add rating and set a GBX 1,350 ($17.59) price objective on shares of Smith & Nephew plc in a research report on Friday, May 5th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company. Smith & Nephew plc has an average rating of Hold and an average target price of GBX 1,285.46 ($16.75).
Smith & Nephew plc (SN) opened at 1329.00 on Friday. The firm’s market cap is GBX 11.64 billion. Smith & Nephew plc has a one year low of GBX 1,064.91 and a one year high of GBX 1,390.00. The firm has a 50 day moving average of GBX 1,333.86 and a 200-day moving average of GBX 1,271.72.
The firm also recently announced a dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Thursday, October 5th will be given a $0.12 dividend. This represents a yield of 0.72%. The ex-dividend date is Thursday, October 5th.
About Smith & Nephew plc
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.
